The primary end point of the study, major molecular response at 12 months, was achieved by 69% of patients. Approximately a ...

Abemaciclib monotherapy benefited 33% of patients with HR-positive, HER2-negative breast cancer post-CDK4/6 inhibitor progression. Abemaciclib shows promise as a monotherapy for HR-positive, ...

Sacituzumab govitecan maintained physical functioning scores, contrasting with chemotherapy's deterioration in advanced TNBC patients. Time to deterioration in fatigue was comparable between ...

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...

Factors associated with higher progression rates included double-hit/triple-hit lymphoma, high IPI status, and primary refractory disease. A recent study reveals critical insights on disease ...

Martin F. Dietrich, MD, assistant professor of internal medicine at the University of Central Florida College of Medicine and ...

Tucatinib addition to trastuzumab and pertuzumab significantly improved PFS in HER2-positive metastatic breast cancer, with a median PFS of 24.9 months versus 16.3 months with placebo. The PFS benefit ...

T-DXd plus pertuzumab improved quality-of-life outcomes, with fewer skin and mucosal symptoms but more gastrointestinal issues compared to the standard regimen. Both treatment arms showed similar pain ...

The TKI plus InO-based therapy for newly diagnosed Ph+ ALL successfully met the efficacy end point, achieving an 81% MR3+ rate within 2 courses with limited cycles of InO. The modified schema 2 ...

Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...

Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...

The ACCESS trial shows mismatched unrelated donors can provide excellent outcomes, addressing racial disparities in donor ...